30 closest matches · ranked by relevance
Non-Hodgkin's Lymphoma · Hodgkins Disease
Primary: Total Number of Subjects With a Complete Response (CR) Following Myeloablative Conditioning (MAC) and Autologous Stem Cell Transplantation (AutoSCT) — 4; 12 Participants
Prolymphocytic Leukemia · Recurrent Adult Hodgkin Lymphoma · Recurrent Childhood Hodgkin Lymphoma
Primary: Engraftment of HLA Identical PBSC Allografts — 53 Participants
Multiple Myeloma
Primary: Proportion of Participants With Relapsed Multiple Myeloma With Progression-free (PFS) — 0.31 Proportion of participants PFS
Lymphoma
Primary: Progression-free Survival — 18 participants
Multiple Myeloma
Primary: Number of Participants Achieving a Complete Response — 51 Participants
Childhood Germ Cell Tumor · Ovarian Cancer · Teratoma
Primary: Overall Survival (OS) — 86; 56 percentage of participants
Lymphoma · HIV
Primary: Overall Survival (OS) — 87.3; 82 percentage of participants
Lymphoma · Myeloma · Leukemia
Primary: Toxicity — 5; 3; 10; 17 participants
Hodgkin's Disease
Primary: Transplant Related Mortality Rate — 1; 6 Participants
B-Cell Prolymphocytic Leukemia · Hypodiploidy · Loss of Chromosome 17p
Primary: Event-Free Survival (EFS) — 9 Participants
Lymphoma
Primary: Number of Participants With 1 Year Progression Free Survival — 112; 102; 1; 2 Participants
Hematologic Malignancies · Bone Marrow Transplant Rejection
Primary: The Proportion of Patients Who Develop Full Donor T Cell Chimerism at Day 30 — 44.9 percentage of participants
Multiple Myeloma
Primary: Progression-Free Survival (PFS) — 46; 43; 33; 40 percentage of patients
Lymphoma · Myeloma · Leukemia
Primary: Toxicity — 21; 25 participants
Systemic Scleroderma
Primary: EFS of Patients Undergoing Transplant — 15 participants
Diffuse, Large B-Cell, Lymphoma · Lymphoma, Low-Grade · T-Cell Lymphoma
Primary: Peripheral Blood All-cell Donor Chimerism — 95 percentage of donor-derived elements
Extramedullary Plasmacytoma · Isolated Plasmacytoma of Bone · Light Chain Deposition Disease
Primary: Median Progression Free Survival (mPFS) — 76.4 months
Lymphoma · Disorder Related to Bone Marrow Transplantation
Primary: Participant's Response According to Physician's Global Assessment of Clinical Condition (PGA) — 19; 6; 0; 0 participants
Allogeneic Stem Cell Transplant · Leukemia · Non-Hodgkins
Primary: Overall Survival of Transplant Patients — 727.5 Days
Diffuse Large Cell Lymphoma Relapsed/Refractory
Primary: Number of Patients Achieving Complete Response (CR) to the Treatment Upon Successful Stem Cell Mobilization — 10 Participants
Hematologic Neoplasms
Primary: Number of Recipients Who Developed Grades I-IV Acute Graft Versus Host Disease (GVHD) Following a Combination of Cyclosporine and a Mini-dose Methotrexate Regimen for…
Chronic Myelogenous Leukemia · Acute Myelogenous Leukemia · Chronic Lymphocytic Leukemia
Primary: Survival and Non-relapse Mortality at Day +200 Using the Miltenyi Reagent System — 43; 4 participants
Adult Acute Lymphoblastic Leukemia in Remission · Adult Acute Myeloid Leukemia in Remission · Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Primary: Progression-free Survival (PFS) Distribution of Patients With HL, NHL, and MM for Each Disease-specific High-dose Therapy Regimen, Estimate Provided for 10-yr PFS…
Myeloproliferative Disorders · Acute Myelogenous Leukemia · Chronic Myelogenous Leukemia
Primary: Number of Participants Who Experienced Transplant Related Mortality — 5; 4 Participants
Hematopoietic/Lymphoid Cancer
Primary: Count of Participants That Experience 1 Year Relapse Free Survival After Undergoing Hematopoietic Stem Cell Transplantation (HSCT) Using the Thomas Jefferson University…
Multiple Myeloma · Plasma Cell Myeloma
Primary: Overall Survival — 68 Months
Lymphoma · Hodgkin's Disease
Primary: Disease-free Survival — 76; 88; 70 percentage of participant
Myelodysplastic Syndrome · Hodgkin's Lymphoma · Non-Hodgkin's Disease
Primary: Percentage of Participants With Grade II-IV Acute Graft Versus Host Disease (GVHD) — 42; 38 percentage of participants
Lymphoma
Primary: 2-year Progression-free Survival — 59 percentage of participants
Anemia, Aplastic · Amegakaryocytic Thrombocytopenia · Diamond-Blackfan Anemia
Primary: Treatment Failures